Self-Buffering Protein Formulations

a technology of protein formulation and buffer, which is applied in the field of protein formulation, can solve the problems of difficult to find a buffer, and the difficulty of finding a suitable buffer for pharmaceutical use can be especially acu

Inactive Publication Date: 2008-12-18
AMGEN INC
View PDF3 Cites 105 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0056]39. A method for treating a subject comprising administering to a subject in an amount and by a route effective for treatment a composition according to any of the foregoing or the following, including a reconstituted lyophilate.

Problems solved by technology

Although there are many buffers in general use, only a limited number are suitable for biological applications and, of these, fewer still are acceptable for pharmaceutical processes and formulations.
As a result, it often is challenging to find a buffer that not only will be effective at maintaining pH but also will meet all the other requirements for a given pharmaceutical process, formulation, or product.
The challenge of finding a suitable buffer for pharmaceutical use can be especially acute for pharmaceutical proteins.
Proteins are susceptible to a variety of pH sensitive reactions that are deleterious to their efficacy, typically many more than affect small molecule drugs.
Buffering agents that catalyze reactions that inactivate and / or degrade one or more other ingredients, moreover, cannot be used in pharmaceutical formulations.
Buffers for pharmaceutical use must have not only the buffer capacity required to maintain correct pH, but also they must not buffer so strongly that their administration deleteriously perturbs a subject's physiological pH.
For instance, buffers that sublime or evaporate, such as acetate and imidazole, generally cannot be relied upon to maintain pH during lyophilization and in the reconstituted lyophilization product.
Other buffers that crystallize out of the protein amorphous phase, such as sodium phosphate, cannot be relied upon to maintain pH in processes that require freezing.
For instance, several otherwise useful buffers, such as citrate at low or high concentration and acetate at high concentration, are undesirably painful when administered parenterally.
They all have undesirable limitations and disadvantages.
And they all have the inherent disadvantage of being an additional ingredient in the formulation, which complicates the formulation process, poses a risk of deleteriously affecting other ingredients, stability, shelf-life, and acceptability to the end user.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Self-Buffering Protein Formulations
  • Self-Buffering Protein Formulations
  • Self-Buffering Protein Formulations

Examples

Experimental program
Comparison scheme
Effect test

example 1

Acid Titrations and Buffer Capacities of Sodium Acetate Buffers in the Range pH 5.0 to 4.0

[0368]A stock solution of known concentration of acetic acid was prepared by diluting ultrapure glacial acetic acid in HPLC grade water and then titrating the pH up to the desired value with NaOH. Stocks were equilibrated to the air and to 21° C. Volumetric standards were prepared at a concentration of 1 N and diluted as necessary with HPLC water.

[0369]One mM, 2.5 mM, 5 mM, 7.5 mM, 10 mM, and 15 mM sodium acetate buffers were prepared by diluting the stock in HPLC water. The solutions were titrated with HCl. 0.2 N HCl was used for the 1, 2.5, and 5 mM solutions, 0.4 N HCl was used for the 7.5 mM solution, and 0.8 N HCl was used for the 10 and 15 mM solutions. The titrations were performed using standard analytical laboratory techniques.

[0370]FIG. 1, Panel A shows the titration data and the least squares trend lines calculated from the data for each solution. The slope of the trend line calculat...

example 2

Base Titrations and Buffer Capacities of Sodium Acetate Buffers in the Range pH 5.0 to 5.5

[0371]Acetate buffer stocks and solutions for titration were prepared as described in Example 1. The solutions were titrated as described in Example 1, except that the solutions were titrated from pH 5.0 to 5.5 and the titrations were done using NaOH instead of HCl. 0.2 N NaOH was used to titrate the 1, 2.5, and 5 mM solutions and 0.4 N NaOH was used for the 7.5, 10, and 15 mM solutions. The results of the titrations are shown in FIG. 2A. The linear dependence of buffer capacity on concentration of acetate buffer is displayed in FIG. 2B.

example 3

Determination of Acetate by HPLC

[0372]Acetate was determined in acetate buffer samples using analytical SE-HPLC. A standard curve for peak areas as a function of acetate concentration was established by analysis of acetate in buffers of known acetate concentration. The amount of acetate in test samples was interpolated from the standard curve. A standard curve is shown in FIG. 3. Nominal and measured amount of acetate in test buffers are tabulated below the standard curve in the figure.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use. The invention in these and other respects can be productively applied to a wide variety of proteins and is particularly useful for making and using self-buffering formulations of pharmaceutical proteins for veterinary and medical use, especially, in particular, for the treatment of diseases in human subjects.

Description

REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation-in-part of and claims full priority benefit of U.S. Provisional Application Ser. No. 60 / 690,582 filed 14 Jun. 2005, which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION[0002]The invention relates to the formulation of proteins, especially pharmaceutical proteins. In particular, it relates to self-buffering biopharmaceutical protein compositions, and to methods for designing, making, and using the compositions. It further relates to pharmaceutical protein compositions for veterinary and / or for human medical use, and to methods relating thereto.BACKGROUND OF THE INVENTION[0003]Many aspects of pharmaceutical production and formulation processes are pH sensitive. Maintaining the correct pH of a finished pharmaceutical product is critical to its stability, effectiveness, and shelf life, and pH is an important consideration in designing formulations for administration that will be accepta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/21A61K38/00A61P43/00A61K39/395
CPCA61K9/08A61K39/39591A61K39/3955A61K47/02C07K16/00C07K16/2803C07K16/2827C07K16/2866C07K16/2875A61P35/00A61P43/00A61K9/28A61K39/395C07K16/241C07K2317/565C07K2317/94C07K2317/21C07K16/2851A61K47/10A61K47/26
Inventor GOKARN, YATIN R.KRAS, EVAREMMELE, RICHARD LOUISBREMS, DAVIDHERSHENSON, SUSAN IRENE
Owner AMGEN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products